To the full analysis
Buyback calculator for Sumitomo Pharma
Sumitomo Pharma stock: key metrics
4506.TSumitomo Pharma had an operating margin of 11.1% and a return on invested capital (ROIC) of 10.9% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 62.0% | 17.4% | 8.7% |
| 2008 | 62.4% | 15.1% | 9.7% |
| 2009 | 60.7% | 11.8% | 7.6% |
| 2010 | 62.4% | 12.1% | 7.1% |
| 2011 | 62.8% | 8.2% | 4.4% |
| 2012 | 63.9% | 5.8% | 2.5% |
| 2013 | 63.5% | 7.2% | 2.9% |
| 2014 | 69.4% | 10.9% | 5.2% |
| 2015 | 71.4% | 6.3% | 4.2% |
| 2016 | 72.7% | 9.2% | 6.1% |
| 2017 | 75.4% | 14.9% | 7.7% |
| 2018 | 74.5% | 17.1% | 11.4% |
| 2019 | 73.6% | 12.5% | 10.6% |
| 2020 | 70.8% | 10.6% | 8.4% |
| 2021 | 70.1% | 13.3% | 10.9% |
| 2022 | 66.3% | 10.1% | 10.1% |
| 2023 | 61.7% | 2.0% | −13.4% |
| 2024 | 49.9% | −0.5% | −100.1% |
| 2025 | 56.5% | 5.6% | 5.9% |
| 2026 | 56.7% | 11.1% | 23.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 7.4% | 11.6% | 5.9% |
| 2008 | 8.0% | 9.9% | 6.4% |
| 2009 | 6.2% | 7.2% | 5.1% |
| 2010 | 6.1% | 6.6% | 3.3% |
| 2011 | 5.2% | 5.1% | 2.8% |
| 2012 | 2.7% | 3.0% | 1.5% |
| 2013 | 2.9% | 3.9% | 1.7% |
| 2014 | 5.0% | 6.4% | 3.0% |
| 2015 | 3.4% | 2.9% | 2.2% |
| 2016 | 5.5% | 6.0% | 3.5% |
| 2017 | 7.6% | 12.0% | 4.0% |
| 2018 | 11.8% | 13.7% | 6.6% |
| 2019 | 9.8% | 11.4% | 5.8% |
| 2020 | 7.7% | 4.2% | 3.2% |
| 2021 | 9.7% | 4.4% | 4.3% |
| 2022 | 9.3% | 3.8% | 4.3% |
| 2023 | −18.3% | 1.3% | −6.6% |
| 2024 | −100.0% | −0.2% | −34.7% |
| 2025 | 13.9% | 4.4% | 3.2% |
| 2026 | 36.5% | 10.9% | 13.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.